Identification and characterization of the blocking function of anti-ED-B-fibronectin antibodies

摘要

1. A polypeptide, characterized in that it contains! (A) portion VH, encoded by nucleic acid sequence SEQ ID NO. 1 (MOR 02610), SEQ ID NO. 17 (MOR 02616), SEQ ID NO. 25 (MOR 02619), SEQ ID NO. 29 (MOR 02622). SEQ ID NO. 33 (MOR 02715), or SEQ ID NO. 37 (MOR 02718)! or H-CDR1, H-CDR2 and H-CDR3 region from any of said sections VH, and! (B) portion VL, encoded by nucleic acid sequence SEQ ID NO. 3 (MOR 02610), SEQ ID NO. 19 (MOR 02616), SEQ ID NO. 27 (MOR 02619), SEQ ID NO. 31 (MOR 02622), SEQ ID NO. 35 (MOR 02715), or SEQ ID NO. 39 (MOR 02718)! or L-CDR1, L-CDR2 and L-CDR3 region from any of said sections VL. ! 2. A polypeptide according to claim 1, characterized in that it comprises a VL portion, the encoded nucleic acid sequence SEQ ID NO. 27 (MOR 02619), or SEQ ID NO. 35 (MOR 02715)! or L-CDR1, L-CDR2 and L-CDR3 region from any of the VL regions. ! 3. A polypeptide according to any one of claims 1 and 2, characterized in that it comprises a portion VH encoded by the nucleic acid sequence SEQ ID NO. 25 (MOR 02619), or SEQ ID NO. 33 (MOR 02715)! or H-CDR1, H-CDR2 and H-CDR3 portions of any of these plots VH. ! 4. A polypeptide according to claim 1, characterized in that it comprises a portion VH encoded by the nucleic acid sequence SEQ ID NO. 1 (MOR 02610) and the VL portion, encoded SEQ ID NO. 3 (MOR 02610) or! H-CDR1, H-CDR2 and H-CDR3 portions of this portion and VH! L-CDR1, L-CDR2 and L-CDR3 from this site portions VL. ! 5. A polypeptide according to claim 1, characterized in that it comprises a portion VH encoded by the nucleic acid sequence SEQ ID NO. 17 (MOR 02616) and the VL portion, encoded SEQ ID NO. 19 (MOR 02616) or! H-CDR1, H-CDR2 and H-CDR3 portions of this portion and VH! L-CDR1, L-CDR2 and L-CDR3 portions of this plot VL. ! 6. A polypeptide according to claim 1, characterized in that it comprises a portion VH encoded by the nucleic acid sequence SEQ ID NO. 25 (MOR 0